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Abstract
The epidemiology of hepatitis C virus
(HCV) infection was studied in an English
teaching hospital over an 18 month period.
A total of 104 HCV antibody positive
patients were referred for further investi-
gation. They were divided into those diag-
nosed through screening (blood donors
and intravenous drug abusers) and those
diagnosed for other reasons, and their
mean ages, known risk factors for HCV
transmission, genotypes, and liver biopsy
histology were analysed. Screened patients
were significantly younger than the others.
No significant difference in age was found
between genotypes. Most patients geno-
typed (69%) were genotype 1. Intravenous
drug abusers had a higher proportion of
subtype la, and patients who acquired
HCV through blood transfusion had a
higher proportion of subtype lb. Liver
biopsy specimens were scored using a
histological activity index for liver inflam-
mation and fibrosis. Patients with subtype
lb had significantly more severe liver
disease than other genotypes when the
histological activity index scores for fibro-
sis were analysed (p<0.05). Liver disease
worsened significantly with age according
to all three histological activity index
scores (portal activity: p<0 01, acinar
activity: p<0 001, fibrosis: p<0.0001).
Liver disease worsened with increased
duration of infection (p<0.002), and
patients who also abused alcohol
presented at a significantly younger age
(cirrhosis, p<0 05, hepatocellular carci-
noma, p<0.02).
(Gut 1996; 38: 269-276)
Keywords: hepatitis C virus, epidemiology, genotype,
blood donors.
Hepatitis C virus (HCV) was cloned and char-
acterised in 1989, and it is now clear that it is
the major cause of post transfusion hepatitis.'
HCV infection commonly results in chronic
disease: at least 50% of patients develop
chronic hepatitis, 20% of whom develop
cirrhosis.' 2 There is also a strong association
between HCV and hepatocellular carcinoma.3 4
The virus is parenterally transmitted and routes
of infection include transfusions of blood and
blood products, abuse of intravenous drugs,
tattoos, and sexual or household transmis-
sion.5-9 Nucleic acid sequence analysis has
shown that HCV is a highly variable virus,
and a system for the nomenclature of HCV
genotypes has been proposed that divides the
virus into six main genotypes.'0 It may be that
some genotypes are associated with more
severe liver disease.11
Many patients who become infected with
HCV are asymptomatic for decades, and
remain undiagnosed until they present with
symptomatic advanced liver disease. Early
diagnosis is important as treatment with alpha
interferon is more likely to be successful in the
asymptomatic stage before progression to
cirrhosis.'2 13 Thus, a knowledge of the preva-
lence and natural history of asymptomatic
HCV related to disease duration and HCV
genotypes has profound health care implica-
tions for resource allocation, as treatment of
chronic HCV with alpha interferon or liver
transplantation is very expensive, and is now a
major factor in any health care budget. It has
been estimated that the cost per year of life
saved in non-cirrhotic patients with chronic
HCV infection treated with interferon is
$71 950.'4 Another illustration of the scale of
the problem is that 97 of 426 (23%) of patients
who had liver transplants performed at the
University of California, San Francisco
between 1988 and 1993 had chronic HCV.15
In the same study, 11 of 59 patients (1 9%)
who underwent liver transplant for seronega-
tive cryptogenic cirrhosis also developed
de novo HCV infection after transplantation.
Serological diagnosis of HCV is made by
screening populations such as blood donors,
intravenous drug abusers, and patients who
present with liver disease of unknown aetiol-
ogy. The initial diagnostic test, using an
enzyme linked immunosorbent assay (ELISA)
to detect antibody to the C-100 antigen, was
found to generate a high frequency of false
positives and false negatives.'6 This obviously
presented serious diagnostic problems in a
disease that could remain asymptomatic for
decades. Second generation ELISAs and con-
firmatory RIBA tests incorporating antigens
from other regions of the HCV genome have
reduced this problem.'6
We previously studied the prevalence of
antibodies to HCV in different populations of
patients in north east England using the first
generation ELISA and RIBA tests: anti-HCV
was detected in 21 of 1120 blood donors
(0. 18%).17 Because of the problems discussed
above with first generation anti-HCV testing,
the aim of this study was to assess the popula-
tion in the north east of England further by
studying the epidemiology, genotypes, and
liver histology of patients diagnosed as HCV
positive by second and third generation assays
at the Freeman Hospital, Newcastle upon
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Tyne, over the 18 months from August 1992
to January 1994.
Methods
All patients who were found to be HCV anti-
body positive at the Freeman Hospital between
August 1992 and January 1994 were included
in the study. HCV antibody results originated
from the Microbiology Department at the
Freeman Hospital, the Northern Regional
Public Health Laboratories, and the National
Blood Service, Newcastle. Anti-HCV was
determined in the three laboratories using
second generation ELISAs supplied by Ortho
Diagnostic systems (Raritan, NJ), Abbott
Laboratories (North Chicago, IL), and United
Biomedical (Hauppage, NY). Confirmatory
immunoblots used were supplied by Ortho
Diagnostic Systems (RIBA-2, RIBA-3) and
Abbott Laboratories (Matrix test). Units of
blood tested at the National Blood Service that
were found to be initially reactive by ELISA-2
were screened again by ELISA-2 in triplicate.
Repeatedly reactive units proceeded to confir-
matory immunoblot testing. Those found to be
indeterminate or positive on confirmatory test-
ing were referred as described below.
Patients were grouped into those identified
through screening and those who presented for
other reasons, including possible liver disease.
Patient details were obtained from case notes.
SCREENED PATIENTS
Patients identified through screening were either
blood donors from the National Blood Service,
Newcastle or known intravenous drug abusers
referred from the Northern Regional Drug
Dependency Unit. Blood donors diagnosed
HCV positive or indeterminate by confirmatory
immunoblot were notified and advised to con-
sult their general practitioners, who referred
them to the specialist liver clinic at the Freeman
Hospital for counselling and assessment.
Intravenous drug abusers were referred directly
from the Drug Dependency Unit to the liver
clinic after counselling and HCV antibody test-
ing. All patients were then seen three times in
the clinic at monthly intervals, for repeat HCV
ELISA and immunoblot serology, together with
three sets of liver function tests. If one or more
of the liver function tests showed a raised
alanine transaminase (ALT>45IU/1) or a raised
alkaline phosphatase (ALP> 11 5IU/1), or both,
a liver biopsy was advised.
OTHER PATIENTS
Other patients were tested for HCV for a
variety of reasons, including those with abnor-
mal liver function tests, patients presenting
with hepatocellular carcinoma, patients
referred to the Freeman Hospital liver trans-
plant programme, and patients who had
received multiple transfusions of blood or
blood products. Most were diagnosed in the
liver clinic, but some were identified from the
records ofHCV tests kept in the Microbiology
Department at the Freeman Hospital. These
included patients from several different hospital
departments such as cardiothoracic surgery and
nephrology, and in these cases patient details
were obtained from their medical records. All
patients seen in the liver clinic were seen three
times at monthly intervals, for repeat HCV
ELISA and immunoblot serology, together
with three sets of liver function tests. If one or
more of the liver function tests showed a raised
ALT (>45IU/1) a raised ALP (>11 51U/l), or
both, a liver biopsy was advised.
GENOTYPING
Plasma samples from HCV antibody positive
patients were collected in EDTA and stored at
-80C until analysis. RNA was extracted using
the method of Chomczynski and Saachi.'8
Genotypes were determined either by reverse
transcription of RNA and polymerase chain
reaction (RT-PCR) followed by restriction
fragment length polymorphism as previously
described,'9 or by RT-PCR and reverse
hybridisation to specific oligonucleotide probes
using the INNO-LIPA genotyping kit
(Innogenetics, Belgium).20
LIVER BIOPSY SPECIMEN ANALYSIS
Seventy five patients included in the study
were biopsed. Liver biopsy specimens were
available for pathological review from 68
patients (four patients who had been biopsied
were HBsAg positive and were excluded from
the liver biopsy study, three specimens were
not available for review). The liver biopsy spec-
imens were assessed independently by two
observers (SJJ, ADB) blinded to the clinical
and serological data. Cases in which there was
a discrepancy in the independent scores were
reviewed by the two pathologists together and
a final grade agreed. The biopsy specimens
were scored according to Scheuer21 for
features of chronic hepatitis:
* Portal/periportal activity (0 - none or mini-
mal, 1 - portal inflammation, 2 - mild piece-
meal necrosis, 3- moderate piecemeal
necrosis, 4 - severe piecemeal necrosis;
* Acinar activity (0 - none, 1 - inflammation
but no necrosis, 2 - focal necrosis or acidophil
bodies, 3 - severe focal cell damage, 4 -
damage includes bridging necrosis; and
* Fibrosis (0 - none, 1 - enlarged fibrotic
portal tracts, 2 - periportal or portal-portal
septa but intact architecture, 3 - fibrosis with
architectural distortion but no obvious cirrho-
sis, 4 - probable or definite cirrhosis).
Results
Number of patients presenting, risk factors,
mean ages, genotypes, liver biopsy histology,
and associations with other hepatic and non-
hepatic diseases were analysed.
NUMBERS OF PATIENTS PRESENTING AND RISK
FACTORS
The distribution of the 104 patients diagnosed
HCV RIBA positive during the 18 month
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TABLE I Numbers, risk factors, associations, and liver biopsy results ofpatients confirmed as hepatitis C virus antibody
positive by RIBA at the Freeman Hospitalfrom August 1992 toJVanuary 1994
Risk factors Associations Liver biopsy
a
1Presentation 2 ; 0Z 4 E
Asymptomatic screening
Blood donors:
RIBA positive, norrnal LFT' 7 3 2 1 1
RIBA positive, abnorrnal LFT 23 6 5 2 6 1 3 2 23
Total blood donors 30 9 7 2 7 0 2 3 0 2 23 0 0
Intravenous drug abusers:
RIBA positive, normal LFT 5 5 1
RIBA positive, abnorrnal LFT 22 22 3 2 16 1
Total IVdrug abusers 27 0 0 0 27 0 0 0 3 3 16 1 0
Others
Abnormal LFT 32 13 5 1 4 5 3 1 1 7 1 1 15
Liver cancer 3 1 1 1 1 3
Referral for liver transplant 4 1 3 1 1 4
Dialysis 4 4
Previous organ transplant 4 4 1 1
Total others 47 15 14 1 4 8 4 1 2 9 12 20 3
Total 104 24 21 3 38 8 6 4 5 14 511 21 3
RFT=liver function test; 5CC=hepatocellular carcinoma.
study is shown in Table I, together with identi-
fiable risk factors and associations. Altogether
94 of 104 (90%) were British born white
people. The remainder included an Italian,
two patients from the United Arab Emirates
referred for transplantation, an Israeli born
Hasidic Jew, and six migrants from Pakistan
and Bangladesh. All patients except two of the
three transplant referrals are now resident in
the north east. Only the Italian (drug use) and
the Israeli (blood transfusion) had recognised
risk factors. The male:female ratio was 61:43
(1.4:1).
SCREENED PATIENTS
Blood donors
A total of 215 291 units were screened between
August 1992 and January 1994 by the Blood
Transfusion Service. Of these, 283 of 215 291
(0. 13%) were repeatedly reactive by ELISA,
and 144 of 215 291 (0-07%) were confirmed
positive or indeterminate by immunoblot.
Altogether 105 of 144 patients were subse-
quently referred by general practitioners
during the 18 months. Thirty of 105 were posi-
tive by confirmatory immunoblot on repeat
testing in the liver clinic. Twenty one of 30 had
identifiable risk factors: seven had previously
had blood transfusions, seven had abused
intravenous drugs without disclosing this
before donating blood, three were health care
workers, one had been tattooed, one had
received acupuncture treatment, and two had a
possible history of sexual or household trans-
mission. Nine of 30 had no identifiable risk
factors.
Intravenous drug abusers
Twenty seven patients were tested and referred
because of previous or current intravenous
drug abuse. All were confirmed RIBA positive.
OTHER PATIENTS
A variety of presentations were seen in the
other 47 HCV RIBA positive patients. Thirty
two presented with abnormal liver function
tests, one of whom subsequently developed
hepatocellular carcinoma. Three presented
with hepatocellular carcinoma, and four pre-
sented for assessment on the liver transplant
programme. Of the four patients referred for
liver transplantation, one was white and had
lived in the north east of England all his life. A
second was an immigrant from Pakistan who
had lived in England for over 20 years. The
other two patients were referred from the
United Arab Emirates for transplantation.
Four were patients on dialysis, and four had
received orthotopic transplants (two kidney,
one heart, and one liver). Thirty two had
identifiable risk factors: 14 had previously had
blood transfusions, four had abused intra-
venous drugs, one was a health care worker,
four had been tattooed, one had a possible
history of sexual or household transmission,
and eight originated from the Middle East or
Indian subcontinent. Fifteen had no identifi-
able risk factors.
MEAN AGES
Blood donors (mean (SD) age 35-6 (6-9)
years) and intravenous drug abusers (mean age
36-0 (6.4) years) were both significantly
younger than patients presenting for other
reasons (mean age 55-3 (16-0) years, Student's
t test p<0-05). The mean (SD) age of patients
with chronic hepatitis was 38-9 (9-5) years, the
mean age of patients with cirrhosis was 60-7
(12-5) years, and the mean age of patients with
hepatocellular carcinoma was 67-3 (5-5) years.
GENOTYPES
Stored plasma samples were available from 73
of 104 RIBA positive patients. Fifty eight of
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Figure 1: Number and percentages ofpatients with
hepatitis C virus genotypes 1-4 (unclassified subtypes
shown as*).
the 73 were HCV RNA positive by PCR. The
distribution of genotypes and subtypes is
shown in Fig 1. The commonest genotype was
genotype 1 (69%), followed by genotype 3
(21%). Subtype analysis revealed 23 patients
with HCV type lb and 15 with type la. The
association ofgenotypes with the main identifi-
able risk factors is shown in Fig 2. Intravenous
drug abusers were most likely to have HCV
subtype 1 a, and patients acquiring HCV
through blood transfusion had a high propor-
tion of subtype lb. Of the three patients of
Middle/Far East origin for whom genotypes
were obtained, one was type 1 a, and two were
type 3. Two patients with HCV type 4 were
identified - one Israeli born Hasidic Jew with
Crohn's disease who had previously received
blood transfusions and one white British health
care worker. No significant difference in age
Transfusion iv drugs
was found between genotypes. The mean age
of all patients genotyped was 45.7 (15.5) years
and the mean age of patients with genotype lb
was 51.9 (18.5) years (t= 1.61, p>0 05).
LIVER BIOPSY HISTOLOGY
Inflammatory changes were present in all
biopsy specimens and ranged widely in severity
from minimal acinar inflammation only to
severe piecemeal necrosis with bridging acinar
necrosis and cirrhosis. There was portal
inflammation in 63 biopsy specimens, 32 of
which showed piecemeal necrosis (17 - mild,
13 - moderate, and two - severe). Six speci-
mens lacked acinar inflammation and 42
showed acinar inflammation but no necrosis.
Acinar inflammation with hepatocyte necrosis
was present in 20 specimens (14 - mild focal
necrosis, two - severe focal damage, and four -
bridging necrosis). Most specimens showed
either no fibrosis (32) or portal tract enlarge-
ment only (11); three specimens showed peri-
portal septa, three severe fibrosis falling short
of cirrhosis, and 19 showed established cirrho-
sis. Portal lymphoid follicles were noted in 24
specimens; the lymphoid follicles varied in size
and occasionally contained germinal centres.
Steatosis was present in 35 specimens (26 -
minimal or mild and nine - moderate or
severe). In occasional biopsy specimens there
was lymphocyte influx into bile duct epithe-
lium. Scoring by the two observers indepen-
dently was found to be broadly in agreement;
most discrepancies were encountered between
the grades of 1 and 2 for portal and acinar
activity, better correlation was obtained for the
higher grades of inflammation and for the
fibrosis scores.
Patients were divided into two groups for
each histological activity index score: those
scoring 0-2 and those scoring 3-4 (moderate
to severe chronic active hepatitis with severe
focal cell damage or bridging necrosis, and
architectural distortion or cirrhosis). HCV
subtype lb was associated with the highest per-
centage of patients scoring 3-4 in all three
index scores (Fig 3). The index scores compar-
ing HCV subtype lb with other subtypes were
tested using Wilcoxon-Mann-Whiiney rank
sum test, ranking index scores from 0-4 for lb
patients and comparing ranks with index
scores for all other genotypes. A value for z of
-1x93 was generated for the fibrosis index
(p<005). Z values for portal activity and
acinar activity were -1 x61 and -0.79 respec-
tively (both not significant). Index scores were
also compared with age. All three histological
activity scores showed a significant correlation
with age (Fig 4A, B, C); the most significant
correlation was seen with the fibrosis score
(=0x659, p<0-0001). Comparison of ALT
activities with histological activity scores
showed a significant difference between acinar
activity scores 0-4 (ANOVA p<0 05), but no
significant differences between portal and
fibrosis scores 0-4 (ANOVA p>0 05 for both).
Biopsy results were also grouped into three
disease states from histology reports issued:
chronic hepatitis, cirrhosis, and hepatocellular
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Figure 2: Association of hepatitis C virus genotypes with risk factors.
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Figure 3: Liver biopsy histological activity index scores in relation to hepatitis C vir
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carcinoma. Disease state was compare(
duration of infection, risk factors, alcohc
sumption, and ALT (IUll, the highest sc
three measured in the liver clinic). The
duration of infection increased as the c
state worsened (Fig 5, ANOVA p<C
Risk factor analysis showed that a high p
tion of intravenous drug users (who were
younger, screened group) had chronic he
(Fig 6). The mean age of patients who
excess alcohol (defined as >21 U/wk fc
>14 U/wk for women) was younger fo
disease state than patients who did not d:
excess (Table II, chronic hepatitis: t=
NS, cirrhosis: t=2.28, p<0 05, hepatoc
carcinoma, t=2-70, p<0 02). All 13
specimens in those patients who drank
alcohol reported the presence of steatos
of 13 also reported Mallory's hyaline.
range of ALT activities was seen wi
significant differences in ALT between c
states, due to the high SD values (AI
p>0'05).
DISEASE ASSOCIATIONS
Six of 27 intravenous drug abusers ha
dence of past or current infection with
tis B. Eleven of 47 of the patients pres
for other reasons had evidence of pastc
rent hepatitis B infection and one of 4
also co-infected with delta virus. Two
donors were HBcAb and HBsAb pc
Non-hepatic disease associations seen
three patients with fibrosing alveolitis, tw
porphyria cutanea tarda, one with
Hodgkin's lymphoma, and one with
cythaemia rubra vera.
Discussion
The prevalence of HCV infection in u.
blood donated in north east England usi
second generation anti-HCV ELISA is 0-13%
(283 of 215 291). A lower prevalence of
0.0 14% (30 of 215 291) was confirmed posi-
tive by immunoblot. This may be an under-
estimate of the prevalence of HCV positive
blood donors over the same period of time
because some HCV negative donors may have
donated more than one unit of blood during
the 18 months of the study.
We have previously studied the prevalence
of antibodies to HCV in different populations
of patients in north east England using the first
generation ELISA and RIBA tests; anti-HCV
was detected in 0.18% blood donors (two of
1120).17 This prevalence is low compared with
other blood donor studies using first genera-
tion assays: reports were 0.61% United
Kingdom,'6 090/o in Japan,5 and 1.3% in
Italy.24 Our more recent blood study using
second generation testing also shows a lower
prevalence than other recently reported series
in the United Kingdom. We find 0.014%
positive on confirmatory immunoblot, com-
pared with 1 in 1400 (0.07%) in north
London,25 and 1 in 2000 (0.05%) in a multi-
centre UK study.26 Six of 10 633 (0.06%)
blood donations from the study reported by
d with Garson'6 were viraemic by HCV-RNA PCR
:1 con- assay and RIBA-2 positive or indeterminate,
core of compared with 65 of 10 633 (0'6%) positive by
mean first generation assays.
lisease Despite the reduction in false positive results
).002). since the introduction of second generation
iropor- tests, problems are still recognised. In this
in the study, 283 blood donors were repeatedly reac-
~patitis tive by ELISA-2 but only 30 of the 283 were
drank subsequently confirmed positive by second
)r men generation immunoblot. Such discrepancies
tr each have been noted before,27 and interpretation of
rink to the significance of RIBA negative and indeter-
=1.82, minate results in ELISA-2 positive blood
ellular donors remains a problem. In one study, 1 00%
biopsy of patients with indeterminate RIBA results
excess and persistently normal liver function tests
is, five were PCR negative and had no liver disease on
k wide biopsy,28 suggesting that these patients are
ith no false positives. Current and future develop-
lisease ments in HCV supplementary test kits may
N4OVA help to improve the specificity of diagnosis.
HCV RNA testing can also help to resolve
these problems, and is now becoming widely
available with the advent of commercially
available HCV PCR kits. However, the prob-
Ld evi- lems are still not entirely resolved with PCR, as
hepati- false positive (due to contamination) and false
,enting negatives (due to inadequate storage of serum
or cur- specimens before testing,29 and the problem of
17 was intermittent viraemia which can be seen in
blood chronic HCV infection30) are well recognised
)sitive. with diagnostic PCR.3'
were The other asymptomatic group screened
ro with was intravenous drug abusers, a group previ-
non- ously noted to have a high frequency of HCV
poly- infection,'7 often with hepatitis B co-infec-
tion.24 During this 18 month study, 27 asymp-
tomatic intravenous drug addicts were seen
and most were found to have HCV related liver
disease on further investigation. Some 22%
nits of (six of 27) had evidence of current or previous
ing the hepatitis B virus infection. This association
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Figure 4: Liver biopsy
histological activity index
scores compared with age:
A acinar activity; B
fibrosis; and C portal
activity.
A Acinar activity
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Histological activity index Histological activity index
risk factors. The other major risk factors
C Portal activity identified in our study were previous blood
transfusions (20%) and intravenous drug
abuse (37%), which are also identified in the
A^ A Royal Free study (27% and 16% respectively).
Ao AS^ 8 When HCV genotypes were compared with
A~ identifiable risk factors, patients with a previ-
10
ous history of blood transfusion were most
A A likely to have genotype lb, and intravenous
r=0-391 drug abusers were most likely to have genotype
t=3-433 1 a. Both these associations have previously
p<001 been reported.37 38 Nearly all of the patients
genotyped were types 1-3, a distribution that
0 has also been previously reported in the United
0 1 2 3 4 Kingdom and Europe. 11 3738
Histological activity index Our data on screened patients indicate that a
significant proportion of HCV in the com-
munity is associated with asymptomatic liver
also seen in other HCV infected patients in disease. Currently, there is no way of diagnos-
,roup studied: a total of 19 of 104 (18%) ing those asymptomatic individuals who do not
evidence of current or previous hepatitis B donate blood, but the natural history of HCV
,infection, in contrast with estimates of related liver disease suggests that a proportion
oximately 0 1% in the UK population as a will develop symptoms in later life, having
le.32 Other previously recognised non- progressed to cirrhosis or hepatocellular carci-
tic disease associations with HCV such as noma. This prolonged delay between HCV
,sing alveolitis,33 porphyria cutaenea infection and symptomatic liver disease is
,'34 and non-Hodgkin's lymphoma35 were reflected in our study in the comparison
seen in this study. between the screened asymptomatic group and
ialysis of identifiable risk factors showed a those hospital patients presenting with sympto-
proportion (24 of 104, 23%) with no matic disease. Blood donors and intravenous=---C. t-r= ----k -- - x- -- __>v.w-
obvious risks. This is similar to a re
reported study from the Royal Free hosp
in which 20% (20 of 102) had no ident
cently drug abusers were both significantly younger
,ital,36 than patients diagnosed for other reasons, with
ifiable the mean age of diagnosis differing by nearly
20 years between the screened and the sympto-
matic group. This is also reflected in the liver
biopsy histology, with a difference in mean age
of over 20 years in those diagnosed as having
chronic hepatitis, compared with those with
cirrhosis and hepatocellular carcinoma. Liver
disease worsened significantly with age accord-
ing to all three histological activity index scores.
It could be that this is because older patients
with mild disease are not symptomatic and have
not been screened, and therefore do not present
in this study. However, as well as the simpler
measure of mean age, the mean duration of
infection also rises as the disease state worsens.
Although it would help our understanding of
the natural history of HCV to screen large
populations of asymptomatic elderly patients, it
may not be justifiable in health economic terms
with the prolonged course of HCV infection
indicating that is is unlikely to progress and
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Figure 6: Association of liver disease with risk factors.
cause problems within the lifespan that remains
to these patients. Excessive alcohol consump-
tion is also seen to accelerate disease progres-
sion. Comparison of mean ALT activities with
liver histology shows no significant association
except with the acinar activity score, supporting
previous reports that the absolute ALT activity
is a poor indicator of the degree of liver disease
seen on biopsy specimen.26 39
The effect of genotype on liver disease has
also been studied. It has been reported that
patients with genotype lb have more severe
liver disease.' The association remains contro-
versial, and it has been postulated that patients
with genotype lb tend to be older and therefore
could have developed more severe liver disease
due to chronicity of infection rather than geno-
type.'1 40 In our study, liver disease was more
severe with genotype lb when the fibrosis
scores from the histological activity index were
analysed, and the effect was independent of age
in the population studied as no significant dif-
ference in age was found between genotypes.
Another possible explanation for the associa-
tion ofHCV genotype lb with more severe liver
disease is the route of transmission. In this
study, post transfusion hepatitis was associated
with genotype lb, and intravenous drug
abusers were more likely to have genotype 1 a. A
high proportion of drug abusers also had mild
liver disease (chronic hepatitis). It could be
postulated that the infecting dose in post
TABLE iI Mean ages and liver biopsy results ofhepatitis C virus infected patients who did
and did not drink to excess (>21 u/wk for men, > 14 u/wk for women, hcc: hepatocellular
carcinoma)
No excess alcohol Excess alcohol
Mean (SD) age No of Mean (SD) age No of
Histology patients patients
Chronic hepatits 39.5 (9.6) 43 34-3 (6.0) 6
Cirrhosis 65-4 (7.8) 13 50.5 (15-1) 6
Hepatocellular carcinoma 70.0 (4.2) 2 62-0 (0.0) 1
0 'a c co 0
r. ~~~~~~~~0
'U1 'U
otCoc0 M~~ 0
Risk factor x
u)
IL
transfusion hepatitis is much higher than in
intravenous drug abuse and this could be
responsible for the more severe disease associ-
ated with genotype lb. There could of course
also be an alternative pathogenetic mechanism
related to HCV genotype, which is as yet
undefined. The severe liver disease associated
with genotype 1, in particular type lb, has
previously been documented, together with a
reduced response rate to alpha interferon. 1 1114
The response to alpha interferon was not
analysed in this study because the number of
patients within the group who have completed
alpha interferon treatment was too small for
statistical purposes.
In summary, our study of a predominantly
British born white patient group indicates that
a significant proportion of asymptomatic HCV
positive individuals diagnosed by screening
have liver disease. The severity of disease may
be influenced by HCV genotype. Our results
suggest that chronic infection of at least 20
years is required before presentation with
symptomatic end stage liver disease, emphasis-
ing the insidious course of HCV infection and
the need for effective screening of asympto-
matic younger individuals. The issue of
whether antiviral treatment should be offered
to all asymptomatic individuals in an attempt
to prevent progressive disease remains unre-
solved, particularly in view of results suggest-
ing that patients with little inflammatory
activity (previously termed 'chronic persistent
hepatitis') may have a good prognosis.42 43 The
role of HCV genotypes in disease severity also
needs further investigation. Future trials of
therapy should be stratified for histological
activity scores and HCV genotype.
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